Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of ENX-102 in healthy volunteers
NL-OMON52117Phase 1Completed
- Sponsor
- Engrail Therapeutics
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ENX-102 (2 arms), sponsored by Engrail Therapeutics. Primary endpoint: Safety and tolerability. Started Nov 2021; status: completed.
02
Drugs
ENX-102
Beyond the preview
Go deeper on NL-OMON52117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52117.